DAWN

Day One Biopharmaceuticals, Inc. · NASDAQ

Performance

-0.16%

1W

-5.4%

1M

-10.68%

3M

-4.48%

6M

-12.4%

YTD

-7.65%

1Y

Profile

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.

Technical Analysis of DAWN 2024-12-20

The stock indicators reflect a bearish sentiment overall, with a Moving Average Score of 10 indicating strong downward pressure, while the Oscillators Score of 53 suggests a neutral stance. The Technical Score of 31 further reinforces the bearish outlook, indicating that caution is warranted in the current market environment.
Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

See more ...

Stock Analysis of DAWN

Stock Rank

See more ...

Recent News & Updates

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.